1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2015

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2015" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 26
Subjects Recruited Over a Period of Time 43
Clinical Trials by Sponsor Type 44
Prominent Sponsors 45
Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 46
Prominent Drugs 47
Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 48
Aug 10, 2015: Gamida Cell Achieves Major Regulatory Milestone: FDA and EMA Respond Positively to NiCord Phase III Study Design Outline 48
Jul 14, 2015: Celator Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Acute Myeloid Leukemia Patients at High Risk for Induction Mortality 48
Jun 29, 2015: The Leukemia and Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 49
Jun 10, 2015: Celyad Completes 30-Day Safety Follow-Up of First Patient in NKG2D Phase I Trial 49
Jun 08, 2015: Celator Pharmaceuticals Announces Expansion of Clinical Study in Patients with Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia at High-Risk of Treatment-Related Mortality 50
Jun 02, 2015: Tolero Pharmaceuticals and Eutropics Announce Results Demonstrating the Predictive Potential of a Biomarker in AML Patient Response to an Alvocidib-containing Regimen 50
Jun 02, 2015: Synta Announces Ganetespib Program Updates 51
Jun 01, 2015: Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk AML 52
May 27, 2015: MacroGenics Preclinical Research on MGD006 DART Molecule Published in Science Translational Medicine 53
May 21, 2015: Calithera Reports Initial Phase I Data for CB-839 in Patients with Acute Leukemias 54
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting 54
Clinical Trial Profiles 55
Clinical Trial Overview of Top Companies 55
Celgene Corporation 55
Clinical Trial Overview of Celgene Corporation 55
Novartis AG 61
Clinical Trial Overview of Novartis AG 61
Sanofi 66
Clinical Trial Overview of Sanofi 66
Pfizer Inc. 71
Clinical Trial Overview of Pfizer Inc. 71
Merck and Co., Inc. 75
Clinical Trial Overview of Merck and Co., Inc. 75
Johnson and Johnson 77
Clinical Trial Overview of Johnson and Johnson 77
Teva Pharmaceutical Industries Limited 79
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 79
Takeda Pharmaceutical Company Limited 81
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 81
GlaxoSmithKline Plc 83
Clinical Trial Overview of GlaxoSmithKline Plc 83
AstraZeneca Plc 85
Clinical Trial Overview of AstraZeneca Plc 85
Clinical Trial Overview of Top Institutes / Government 87
National Cancer Institute 87
Clinical Trial Overview of National Cancer Institute 87
The University of Texas M. D. Anderson Cancer Center 122
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 122
Fred Hutchinson Cancer Research Center 130
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 130
Memorial Sloan Kettering Cancer Center 138
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 138
Children's Oncology Group 142
Clinical Trial Overview of Children's Oncology Group 142
Sidney Kimmel Comprehensive Cancer Center 144
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 144
European Organization for Research and Treatment of Cancer 146
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 146
PETHEMA 148
Clinical Trial Overview of PETHEMA 148
Washington University School of Medicine 150
Clinical Trial Overview of Washington University School of Medicine 150
Case Comprehensive Cancer Center 152
Clinical Trial Overview of Case Comprehensive Cancer Center 152
Five Key Clinical Profiles 154
Appendix 270
Abbreviations 270
Definitions 270
Research Methodology 271
Secondary Research 271
About GlobalData 272
Contact Us 272
Disclaimer 272
Source 273

List of Tables
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2015* 8
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 14
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 15
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2015* 16
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2015* 19
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2015* 22
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Suspended Clinical Trials, 2015* 26
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Withdrawn Clinical Trials, 2015* 28
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Terminated Clinical Trials, 2015* 31
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 43
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 44
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 45
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 46
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 47
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2015* 55
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 61
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2015* 66
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2015* 75
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2015* 77
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2015* 79
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2015* 81
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline Plc, 2015* 83
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 85
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 87
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2015* 122
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2015* 130
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 138
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2015* 142
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2015* 144
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2015* 146
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by PETHEMA, 2015* 148
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2015* 150
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2015* 152

List of Figures
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 14
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 15
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2015* 16
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2015* 19
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 43
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 44
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 45
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 46
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 47
GlobalData Methodology 271

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.